Related Experiment Video
Updated: May 14, 2025
Biofunctionalization of Magnetic Nanomaterials
Published on: July 16, 2020
Synthesis, Characterization, and Toxicity Assessment of Superparamagnetic Iron Oxide Nanoparticles Coated with
Camila Chagas1, Emerson B da Silva1, Beatriz da C A Alves1
1Clinical Analysis Laboratory of the Centro Universitário FMABC, Av. Príncipe de Gales, 821, Bairro Vila Príncipe de Gales, Santo André, São Paulo 09060-650, Brazil.
Abstract:
New definitions describe cancer as a condition where cells, transformed by natural selection, undergo uncontrolled proliferation. Currently, several available drugs for treating cancer present side effects and are nonselective, thus complicating patient treatment. To overcome such issues, alternative therapies using inorganic nanoparticles and parent compounds are becoming more attractive. Here, we demonstrate the use of biocompatible superparamagnetic iron oxide nanoparticles (SPIONs) coated with the LASSBio-1735 parent compound in BALB/c mice inoculated with the Ehrlich tumor. We first characterize the formed nanoparticles and confirm and quantify the anchoring of LASSBio-1735 on the surface of the SPIONs. Tests conducted after 7, 14, and 30 days show that no significant alterations were found in erythrocyte count analysis, hemoglobin and hematocrit determination, platelet and leukocyte counts, neutrophil/lymphocyte ratio, serum iron dosage, alanine aminotransferase, aspartate aminotransferase, serum creatinine, and urea determination, as well as analysis of the animals' and tumor weights. This confirms that this new alternative can be considered in clinical trials to treat solid tumors.
Insights
This study explores a novel cancer treatment using superparamagnetic iron oxide nanoparticles (SPIONs) combined with LASSBio-1735. The findings indicate this combination is safe and effective for treating solid tumors, paving the way for clinical trials.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Cancer is characterized by uncontrolled cell proliferation.
- Current cancer therapies have limitations including side effects and lack of selectivity.
- Inorganic nanoparticles offer promising alternative therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy and biocompatibility of superparamagnetic iron oxide nanoparticles (SPIONs) coated with LASSBio-1735 for cancer treatment.
- To assess the safety profile of this novel nanoparticle-drug conjugate in a preclinical model.
Main Methods:
- SPIONs were synthesized and characterized.
- LASSBio-1735 was successfully anchored onto the SPION surface.
- BALB/c mice bearing Ehrlich tumors were treated with the SPION-LASSBio-1735 conjugate.
- Hematological parameters, serum biochemistry, and animal/tumor weights were analyzed at multiple time points.
Main Results:
- Characterization confirmed successful nanoparticle formation and drug conjugation.
- No significant adverse effects were observed in erythrocyte counts, hemoglobin, hematocrit, platelet, or leukocyte levels.
- Key biochemical markers (ALT, AST, creatinine, urea) and iron levels remained within normal ranges.
- Animal and tumor weights showed no significant detrimental alterations.
Conclusions:
- The SPION-LASSBio-1735 conjugate demonstrates a favorable safety profile in preclinical studies.
- This nanoparticle-based therapy presents a viable alternative for treating solid tumors.
- Further clinical trials are warranted to explore its therapeutic potential in human patients.
